Drugs / NXN-462
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01748877 | Jan 2013 → Jun 2014 | postherpetic neuralgia | NeurAxon Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NXN-462 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01748877 ↗ |
| Action | Inhibit | “By design, NXN-462 is a potent inhibitor of nNOS” NCT01748877 ↗ |
| Route | Oral | “NXN-462 is being developed as an oral therapy” NCT01748877 ↗ |